We are live on ! Find out more
EW icon

Edwards Lifesciences

1,204 hedge funds and large institutions have $36.6B invested in Edwards Lifesciences in 2025 Q1 according to their latest regulatory filings, with 121 funds opening new positions, 387 increasing their positions, 489 reducing their positions, and 123 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $257M | Put options by funds: $178M

1.04% more ownership

Funds ownership: 85.24%86.28% (+1%)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

2% less first-time investments, than exits

New positions opened: 121 | Existing positions closed: 123

3% less capital invested

Capital invested by funds: $37.6B → $36.6B (-$950M)

2% less funds holding

Funds holding: 1,2261,204 (-22)

21% less repeat investments, than reductions

Existing positions increased: 387 | Existing positions reduced: 489

Holders
1,204
Holders Change
-22
Holders Change %
-1.79%
% of All Funds
16.14%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
121
Increased
387
Reduced
489
Closed
123
Calls
$257M
Puts
$178M
Net Calls
+$79.4M
Net Calls Change
-$243M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
326
Estate Counselors
Wisconsin
$4.43M +$4.38M +61,130 New
NIM
327
NEOS Investment Management
Connecticut
$4.41M +$200K +2,801 +5%
HP
328
HealthInvest Partners
Sweden
$4.33M -$616K -8,600 -13%
LMIM
329
Lockheed Martin Investment Management
Maryland
$4.3M -$99.5K -1,390 -2%
BT
330
Banque Transatlantique
France
$4.26M -$1.09M -15,267 -21%
PA
331
Parallel Advisors
California
$4.24M -$517K -7,229 -11%
CIP
332
Capital Insight Partners
Arizona
$4.16M -$363K -5,077 -8%
CS
333
Candriam SCA
Luxembourg
$4.11M -$4.94M -69,029 -55%
LGF
334
LGT Group Foundation
Liechtenstein
$4.09M -$154K -2,152 -4%
BAMF
335
BI Asset Management Fondsmaeglerselskab
Denmark
$4.07M -$1.18M -16,432 -23%
EI
336
Ethic Inc
New York
$4.04M +$1.13M +15,775 +39%
Cetera Investment Advisers
337
Cetera Investment Advisers
Illinois
$4.02M +$3.97M +55,502 New
TCM
338
Telos Capital Management
California
$4.01M +$262K +3,665 +7%
Los Angeles Capital Management
339
Los Angeles Capital Management
California
$3.99M +$3.73M +52,086 +1,751%
WSCM
340
Wellington Shields Capital Management
New York
$3.97M -$644K -9,001 -14%
EGM
341
Engineers Gate Manager
New York
$3.96M +$3.91M +54,663 New
Rafferty Asset Management
342
Rafferty Asset Management
New York
$3.96M -$879K -12,276 -18%
MC
343
Moors & Cabot
Massachusetts
$3.88M -$76.2K -1,065 -2%
BAM
344
Bell Asset Management
Australia
$3.86M -$66.6K -930 -2%
RIM
345
Rakuten Investment Management
Japan
$3.82M +$3.86M +53,908 New
UM
346
UniSuper Management
Australia
$3.77M +$100K +1,400 +3%
HCG
347
Haven Capital Group
California
$3.73M -$54.7K -764 -1%
OPERF
348
Oregon Public Employees Retirement Fund
Oregon
$3.67M +$9.3K +130 +0.3%
CAPTRUST Financial Advisors
349
CAPTRUST Financial Advisors
North Carolina
$3.64M +$36.2K +506 +1%
Kovitz Investment Group Partners
350
Kovitz Investment Group Partners
Illinois
$3.63M +$490K +6,842 +16%

EW Hedge Fund Activity: Q1 2025 in Review

1,204 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2025, worth a combined $36.6B — down 2.5% from $37.6B a quarter earlier.

Sellers outnumbered buyers: 123 funds closed out of EW and 121 opened new positions — a net loss of 2 holders — while 489 trimmed existing stakes and 387 added.

The largest buyer was JP Morgan Chase, adding an estimated $509M. The largest seller was Wellington Management Group, cutting an estimated $292M.

  • 1,204 institutional investors held Edwards Lifesciences (EW) as of Q1 2025, down from 1,226 in Q4 2024.
  • Funds reported $36.6B of Edwards Lifesciences stock for Q1 2025, down 2.5% quarter-over-quarter.
  • 121 funds opened new Edwards Lifesciences positions in Q1 2025 and 123 closed out, a net change of -2 holders.
  • The largest Edwards Lifesciences buyer in Q1 2025 was JP Morgan Chase, an estimated $509M added.
  • The largest Edwards Lifesciences seller in Q1 2025 was Wellington Management Group, an estimated $292M sold.

Based on aggregated 13F filings for Q1 2025.